{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.63","value":"-7.9"},{"groupId":"OG001","spread":"10.93","value":"-7.4"}]}],"title":"Disease Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.62","value":"4.7"},{"groupId":"OG001","spread":"5.45","value":"7.0"}]}],"title":"Side Effects of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.63","value":"4.8"},{"groupId":"OG001","spread":"21.06","value":"0.0"}]}],"title":"Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.06","value":"11.1"},{"groupId":"OG001","spread":"34.92","value":"7.4"}]}],"title":"Future Perspective"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 is a myeloma-specific module developed by the EORTC group specifically to assess quality of life in participants with multiple myeloma. It contains 20 items which can be grouped into a disease symptom subscale (6 items), side effects of treatment subscale (10 items), body image (1 item) and future perspective subscale (3 items). All transformed scale scores range from 0 to 100 with higher scores indicating worse symptoms (Disease Symptoms and Side Effects of Treatment) or better support/functioning (Future Perspective and Body Image).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG000","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG001","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"}],"paramType":"MEAN","populationDescription":"The PRO Analysis Set included all participants with a baseline and at least one post-baseline measurement of any PRO measure (EORTC QLQ-MY20 or EQ-5D-5L). Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 9 Day 8 [cycle length was 28 days] (up to 7.7 months)","title":"Part 3: Patient-reported Outcome (PRO): Change From Baseline to Cycle 9 in Instrument European Organisation for Research and Treatment of Cancer QLQ Questionnaire Multiple Myeloma Module (EORTC QLQ-MY20)","type":"SECONDARY","unitOfMeasure":"score on a scale"}